Celltrion starts global Phase 3 clinical trials on Remsima’s SC type
In order to secure competitiveness in the TNF-α inhibitor(autoimmune disease therapy) market, Celltrion will start the global Phase 3 clinical trial of the Remsima’s SC type(subcutaneous injection) as a two-track strategy on Remsima.
The Remsima’s safety and pharmacokinetics were already proven ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
